Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of <i>Mycobacterium avium</i> Infection
Jean‐Philippe Lanoix, Cédric Joseph, François Peltier, Sandrine Castelain, C. Andréjak
Abstract
Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of Mycobacterium avium . In an aerosol infection BALB/c mouse model using M. avium strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg.
Topics & Concepts
ClofazimineEthambutolClarithromycinNontuberculous mycobacteriaMicrobiologyMycobacterium avium-intracellulare infectionMycobacteriumRifabutinIn vivoMycobacterium abscessusAerosolizationAntibioticsAntibacterial agentMycobacterium avium complexMycobacterium chelonaeMedicineBiologyImmunologyTuberculosisRifampicinPathologyInhalationAnatomyBiotechnologyLeprosyMycobacterium research and diagnosisTuberculosis Research and EpidemiologyQuinazolinone synthesis and applications